MoonLake Immunotherapeutics - Class A — 財務諸表 (NASDAQ:MLTX) | MetaTrader

チャート全体を表示

ニュース

Clear Street、IL-17データを受けてMoonlake株の目標株価を引き上げ

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgeraldが軸性脊椎関節炎の可能性を評価しMoonlake株のレーティングを再確認

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

H.C. Wainwright、治験結果を受けてMoonlake Immunotherapeutics目標株価を40ドルに引き上げ

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake株、軸性脊椎関節炎試験の良好なデータで急騰

MoonLake stock surges on positive axSpA trial data

InvestingProの適正価値判定後、MoonLake株が63%急騰